Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Jun 1;316(6):313.
doi: 10.1007/s00403-024-03053-6.

Split-scalp pilot study to evaluate effectiveness of Minoxidil 0,5% MMP® versus Topical Minoxidil 5% in the treatment of Female Pattern Hair Loss

Adriana C Corrêa  1 , Carla J Machado  2 , Sueli C S Carneiro  3
Affiliations
Comparative Study

Split-scalp pilot study to evaluate effectiveness of Minoxidil 0,5% MMP® versus Topical Minoxidil 5% in the treatment of Female Pattern Hair Loss

Adriana C Corrêa et al. Arch Dermatol Res. .

Abstract

Female Pattern Hair Loss (FPHL) is a common form of non-scaring hair loss that occurs in adult women. Although several treatments have already been proposed for FPHL, only Topical Minoxidil accumulated an adequate level of evidence. This study aimed to evaluate the therapeutic response of MMP® (intradermal infiltration) of Minoxidil formulation in the frontal-parietal-vertex regions compared with the gold-standard home administration of Minoxidil 5% Capillary Solution. This self-controlled comparative study evaluated 16 FPHL patients, without treatment for at least 6 months, confirmed by trichoscopy with TrichoLAB® software. They received 4 monthly sessions of MMP® with Minoxidil 0,5% on the right side of the scalp (frontal-parietal-vertex areas), followed by occlusion with plastic film for 12 h and prescription of Minoxidil 5% Solution for home use once a day, on both scalp sides, starting 72 h after the procedure. The reassessment trichoscopy was 6 weeks after the last session and they answered a "self-assessment" questionnaire. Treated scalp areas were compared and showed both treatments, in general, were effective, with no difference between them. If they were analyzed separately by treated areas, there were signs of better response in the parietal-vertex regions with treatment by MMP® with Minoxidil, while clinical treatment indicated a better response in the other regions. When patients were divided into more and less advanced cases, a better response in parietal-vertex regions treated by MMP® with Minoxidil in less advanced patients was confirmed. MMP® with Minoxidil showed a better response in the parietal-vertex regions in less advanced FPHL patients. It represents yet another resource to improve quality of life of these suffering patients.

Keywords: Androgenetic alopecia; Female Pattern Hair Loss; Medicine microinfusion into the skin (MMP®); Minoxidil; Scalp microinfusion; Transdermal drug delivery.

PubMed Disclaimer

References

    1. Almeida RFC, Melo DF, Tosti A (2023) Scalp Microinfusion: A Novel Drug Delivery Technique for Hair Loss Treatment. Skin Appendage Disord. 9(2):81–83. https://doi.org/10.1159/000528446 - DOI
    1. Alsalhi W, Alalola A, Randolph M, Gwillim E, Tosti A (2020) Novel drug delivery approaches for the management of hair loss. Expert Opin Drug Deliv 17(3):287–295. https://doi.org/10.1080/17425247.2020.1723543 - DOI - PubMed
    1. Arbache S, Godoy CE (2013) Microinfusion of drugs into the skin with tattoo equipment. Surg Cosmet Dermatol 5(1):70–74
    1. Arbache S, Mattos EDC, Diniz MF, Paiva PYA, Roth D, Arbache ST et al (2019) How much medication is delivered in a novel drug delivery technique that uses a tattoo machine? Int J Dermatol 58(6):750–755. https://doi.org/10.1111/ijd.14408 - DOI - PubMed
    1. Arbache S, Roth D, Steiner D, Breunig J, Michalany NS, Arbache ST et al (2018) Activation of melanocytes in idiophatic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: preliminary analysis of a randomized, split-body, single blinded, placebo controlled clinical trial. J Am Acad Dermatol 78(1):212–215. https://doi.org/10.1016/j.jaad.2018.05.1238 - DOI - PubMed

Publication types

LinkOut - more resources